Following treatment with androgen receptor (AR) pathway inhibitors,≈ 20% of prostate
cancer patients progress by shedding their AR‐dependence. These tumors undergo …

A major hurdle in the study of rare tumors is a lack of existing preclinical models.
Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of …

Purpose: Prostate cancer translational research has been hampered by the lack of
comprehensive and tractable models that represent the genomic landscape of clinical …

Tumours adapt to increasingly potent targeted therapies by transitioning to alternative
lineage states. In prostate cancer, the widespread clinical application of androgen receptor …

Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy.
The development of new CRPC treatment strategies is strongly impeded by the scarcity of …

Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the
mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo …

With advances in the discovery of the clinical and molecular landscapes of prostate cancer
(PCa), implementation of precision medicine-guided therapeutic testing in the clinic has …

Standardized and reproducible preclinical models that recapitulate the dynamics of prostate
cancer are urgently needed. We established a bank of transplantable patient-derived …

Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined,
due to lack of experimental models that mimic different disease stages. We describe an …

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …